Clinical efficacy of eperisone in the treatment of patients with musculoskeletal pain

Objective. To study the clinical efficacy and safety of epirisone hydrochloride (Stezium) in the treatment of patients with skeletal muscle pain. Material and methods. One hundred forty-two 142 patients with non-specific musculoskeletal pain, mean age 46.2±17.8 years, have been enrolled in the study. The study was conducted according to the registered indication for Stezium — diseases of the musculoskeletal system accompanied by painful muscle spasms. Patients received Stezium 75 mg, extended-release, film-coated tablets, twice a day after meals for 14 days. All patients had undergone clinical examination before the prescription of the drug and on the 15th day using a visual analogue scale (VAS), a verbal analogue scale for pain assessing, a visual analogue scale (EQ-VAS) for the European Quality of Life Questionnaire (EQ-5D-3L), and patient assessment of the treatment effectiveness with Likert scale. Results. Quantitative indicators of pain assessment using analog scales statistically significant decreased (p<0.001) against the background of the treatment with Stezium, which indicates a significant analgesic effect of the therapy. Analysis of patient’s health condition showed an increase in the quality of life (from 60.22±10.45 to 74.11±11.53 points; p<0.001), which confirms the effectiveness of the performed therapy. The patient’s assessment of the overall treatment effect on the Likert scale demonstrated positive trend — 85.21% of patients noted significant clinical effect. Conclusion. The study results demonstrated the clinical efficacy and safety of extended-release film-coated tablets eperisone hydrochloride 75 mg for the treatment of musculoskeletal pain.